Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan

References

• Chalmers J, Arima H, Hata J. Cost-effective reduction in stroke: lessons from the Japanese hypertension detection and control program. J Hypertens. 2012(30):1706–1707.
   Google Scholar
• Takashima N, Arima H, Kita Y, et al. Incidence, management and short-term outcome of stroke in a general population of 1.4 Million Japanese- Shiga stroke registry. Circ J. 2017;81:1636–1646.
   PubMed Web of Science ®Google Scholar
• Hata J, Ninomiya T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation. 2013;128(11):1198–1205.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847.
   PubMed Web of Science ®Google Scholar
• Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Bmj. 2016;354:i4482.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760–1764.
   PubMed Web of Science ®Google Scholar
• Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009;137:102–107.
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Okayama A, Sakata K, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol. 2005;15:194–196.
   PubMed Web of Science ®Google Scholar
• Ono K Guidelines on pharmacotherapy of cardiac arrhythmias (JCS/JHRS 2020). (in Japanese). [cited 2020 Mar 13]. Avialable from: https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Ono.pdf
   Google Scholar
• Nakamura M, Kimura K, Kimura T, et al., JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84(5):831–865.
   Web of Science ®Google Scholar
• Group, JCSJW. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014;78:1997–2021.
   PubMed Web of Science ®Google Scholar
• Group, JCSJW. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010;74:2479–2500.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama. 2001;285:2864–2870.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J. 2012;76:2104–2111.
   PubMed Web of Science ®Google Scholar
• Wang KL, Lip GY, Lin SJ, et al. Non-Vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015;46:2555–2561.
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm, A, European Association for Cardio-Thoracic, S, Camm, AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;2016(37):2893–2962.
   Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al., AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;2014(64):e1–76.
   Web of Science ®Google Scholar
• Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy–pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015;79:432–438.
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–546.
   PubMed Web of Science ®Google Scholar
• Hart RG, Sherman DG, Easton JD, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:674–681.
   PubMed Web of Science ®Google Scholar
• Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309–315.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817–821.
   PubMed Web of Science ®Google Scholar
• Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Int Med. 2001;40:1183–1188.
   PubMed Web of Science ®Google Scholar
• Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J. 2013;77:2264–2270.
   PubMed Web of Science ®Google Scholar
• Kodani E, Atarashi H, Inoue H, et al. Use of warfarin in elderly patients with non-valvular atrial fibrillation – subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:2345–2352.
   PubMed Web of Science ®Google Scholar
• Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013;61:260–266.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (Age >/= 85 Years) Japanese patients with atrial fibrillation: the Fushimi AF registry. Chest. 2016;149:401–412.
   PubMed Web of Science ®Google Scholar
• Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78:2166–2172.
   PubMed Web of Science ®Google Scholar
• Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75:1328–1333.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Fukuda S, Nakamura M, et al. Predictors of Cardioembolic Stroke in Japanese Patients with Atrial Fibrillation in the Fushimi AF Registry. Cerebrovasc Dis Extra. 2018;8:50–59.
   PubMed Web of Science ®Google Scholar
• Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612–617.
   PubMed Web of Science ®Google Scholar
• Hamatani Y, Ogawa H, Uozumi R, et al. Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. Circ J. 2015;79:1009–1017.
   PubMed Web of Science ®Google Scholar
• Kodani E, Atarashi H, Inoue H, et al. Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation- results of the J-RHYTHM registry 2. Circ J. 2016;80:843–851.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Otsuka T, Sagara K, et al. Nine-year trend of anticoagulation use, thromboembolic events, and major bleeding in patients with non-valvular atrial fibrillation- shinken database analysis. Circ J. 2016;80:639–649.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Uozumi R, Hamatani Y, et al. Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients- Fushimi AF Registry. Circ J. 2017;81:1278–1285.
   PubMed Web of Science ®Google Scholar
• Masunaga N, Abe M, Ogawa H, et al. Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation- The Fushimi AF Registry. Circ J. 2018;82:2983–2991.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597–2604.
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779–2790.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Pieper K, et al. Frequency and Outcomes of reduced dose non-vitamin K antagonist anticoagulants: results From ORBIT-AF II (The outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7. DOI:10.1161/JAHA.117.007633.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Yokoyama K, Matsumoto N, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm. 2017;33:289–296.
   PubMed Web of Science ®Google Scholar
• Ono T, Kohsaka S, Takatsuki S, et al. Inconsistent dosing of non-vitamin K oral anticoagulants: differences between the United States and Japan. J Am Coll Cardiol. 2017;70:118.
   PubMed Web of Science ®Google Scholar
• Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. J Arrhythm. 2015;31:339–344.
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. 2015. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17:514–523.
   Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
   PubMed Web of Science ®Google Scholar
• Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447–451.
   PubMed Web of Science ®Google Scholar
• Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019;119:149–162.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong YH, Goto S, et al. Expert consensus document: world Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI, Nature reviews. Cardiology. 2014;11:597–606.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–1115.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513–1524.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–1524.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335–1343.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–1393.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;2018(39):213–260.
   Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240–261.
   PubMed Web of Science ®Google Scholar
• Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease Beyond 1 year after coronary stent implantation. Circulation. 2019;139:604–616.
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103–1113.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017;70:2964–2975.
   PubMed Web of Science ®Google Scholar
• Aonuma K, Yamasaki H, Nakamura M, et al. Percutaneous WATCHMAN left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism- first results from the SALUTE trial. Circ J. 2018;82:2946–2953.
   PubMed Web of Science ®Google Scholar